Botfet / Company detail

NRIX

rejected

Nurix Therapeutics, Inc.

biotech

Moat scoreNot available: not scored quality failout of 100
Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context
Roic-47.3%
Gross Margin77.5%
Revenue Cagr29.6%
Fcf Conversion99.6%
Fcf Yield-9.5%
Interest Coverage0.0x
Market Cap B$2.8B
PeNot available: not applicable loss making
Quality PassFail
Founder LedNo
Thesis AlignedYes
Moat QuantNot available: not scored quality fail

Why it may endure

Moat breakdown

Quant: Not available: not scored quality fail · Curator: Not available: not scored quality fail
Market Share StabilityNot available: not scored quality fail
Network EffectsNot available: not scored quality fail
Pricing PowerNot available: not scored quality fail
Regulatory MoatNot available: not scored quality fail
Switching CostsNot available: not scored quality fail
ConvictionNot available: not scored quality fail
LeadershipNot available: not scored quality fail
VisionNot available: not scored quality fail
← Back to the full screener